Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.83 From HK$10.07, Keeps at Buy

MT Newswires04:32 ET · Ratings

CSPC Pharmaceutical Group Limited's (HKG:1093) Intrinsic Value Is Potentially 77% Above Its Share Price

Simply Wall StJul 12 19:59 ET

CSPC Pharmaceutical Group's Respiratory Vaccine Gets NMPA's Nod for Clinical Trials

MT NewswiresJul 12 02:05 ET

Changjiang Securities: The vitamins D3 market is good and the business outlook is positive.

Vitamin D3 is a minor variety in the vitamins industry, mainly used in the field of fodder. With the gradual digestion of overseas market inventory and the steady recovery of domestic demand, the product demand side has been catalyzed marginally. As a high-quality industry with highly concentrated supply of raw materials, the leading players have a greater say and prices have greater elasticity.

Zhitong FinanceJul 11 23:48 ET

CSPC Pharma (01093.HK): Respiratory syncytial virus mRNA vaccine (SYS6016) receives clinical trial approval.

On July 11th, Gelonhui reported that CSPC Pharma (01093.HK) announced that the respiratory syncytial virus (RSV) mRNA vaccine (SYS6016) developed by the group has obtained approval from the China National Medical Products Administration and can conduct clinical trials in China. According to the disclosure, the product is composed of a lipid nanoparticle that packages mRNA molecules encoding the pre-fusion conformation of the full-length fusion glycoprotein (F protein) of respiratory syncytial virus. It is suitable for preventing lower respiratory tract diseases caused by RSV infections. Preclinical studies have shown that the product is translated into pre-fusion conformation F protein in the body and induces ...

Gelonghui FinanceJul 11 05:23 ET

Express News | CSPC Pharmaceutical - Mrna Rsv Vaccine Obtains Clinical Trial Approval From Nmpa

ReutersJul 11 05:22 ET